The University of Chicago Header Logo

Connection

Barry G. Arnason to Multiple Sclerosis

Back to Details
This is a "connection" page, showing publications Barry G. Arnason has written about Multiple Sclerosis.
Barry G. Arnason
Connection Strength
5.225
Multiple Sclerosis
  1. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler. 2013 Feb; 19(2):130-6.
    View in: PubMed
    Score: 0.368
  2. MS Forum/MS Over the Past 17 Years. Int MS J. 2011 Sep; 17(3):76-82.
    View in: PubMed
    Score: 0.342
  3. Tumour Necrosis Factor Neutralization in MS: A Cautionary Tale. Int MS J. 2011 May; 17(2):63-8.
    View in: PubMed
    Score: 0.334
  4. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis. J Neurol. 2005 Sep; 252 Suppl 3:iii28-iii33.
    View in: PubMed
    Score: 0.225
  5. Interferon-ß corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019 Nov; 49:269-283.
    View in: PubMed
    Score: 0.150
  6. Treatment of multiple sclerosis with interferon beta. Biomed Pharmacother. 1999 Sep; 53(8):344-50.
    View in: PubMed
    Score: 0.149
  7. Immunologic therapy of multiple sclerosis. Annu Rev Med. 1999; 50:291-302.
    View in: PubMed
    Score: 0.142
  8. Correlation of the appearance of anti-interferon antibodies during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies. J Interferon Cytokine Res. 1998 Aug; 18(8):639-44.
    View in: PubMed
    Score: 0.138
  9. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Mult Scler. 2019 04; 25(4):565-573.
    View in: PubMed
    Score: 0.134
  10. All-trans retinoic acid potentiates the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis. Arch Neurol. 1998 Mar; 55(3):315-21.
    View in: PubMed
    Score: 0.134
  11. Role of interferons in demyelinating diseases. J Neural Transm Suppl. 1997; 49:117-23.
    View in: PubMed
    Score: 0.124
  12. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
    View in: PubMed
    Score: 0.123
  13. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol. 1996 Oct; 81(1):1-11.
    View in: PubMed
    Score: 0.121
  14. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016 Jul; 263(7):1418-26.
    View in: PubMed
    Score: 0.118
  15. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol. 1996; 18(1):125-48.
    View in: PubMed
    Score: 0.115
  16. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015 Dec; 72(12):1458-65.
    View in: PubMed
    Score: 0.115
  17. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 1995 Dec; 45(12):2173-7.
    View in: PubMed
    Score: 0.115
  18. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995 Jun; 45(6):1097-100.
    View in: PubMed
    Score: 0.111
  19. Nervous system-immune system interactions and their role in multiple sclerosis. Ann Neurol. 1994; 36 Suppl:S29-32.
    View in: PubMed
    Score: 0.100
  20. Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol. 1993 Jul; 46(1-2):123-8.
    View in: PubMed
    Score: 0.097
  21. Interferon beta in multiple sclerosis. Neurology. 1993 Apr; 43(4):641-3.
    View in: PubMed
    Score: 0.095
  22. Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. J Neuroimmunol. 1992 Feb; 36(2-3):171-7.
    View in: PubMed
    Score: 0.088
  23. Multiple sclerosis: additional thoughts. J Neurol Sci. 1992 Feb; 107(2):141-4.
    View in: PubMed
    Score: 0.088
  24. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
    View in: PubMed
    Score: 0.087
  25. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol. 1991 Jul; 30(1):42-7.
    View in: PubMed
    Score: 0.084
  26. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol. 1990 Apr; 27(4):366-72.
    View in: PubMed
    Score: 0.077
  27. Blood lymphocyte beta-adrenergic receptors in multiple sclerosis. Ann N Y Acad Sci. 1988; 540:585-8.
    View in: PubMed
    Score: 0.066
  28. Immunoregulation in rapidly progressive multiple sclerosis. Ann N Y Acad Sci. 1988; 540:4-12.
    View in: PubMed
    Score: 0.066
  29. Immunologic aspects of neurological and neuromuscular diseases. JAMA. 1987 Nov 27; 258(20):2970-3.
    View in: PubMed
    Score: 0.066
  30. Suppressor and cytolytic cell function in multiple sclerosis. Effects of cyclosporine A and interleukin 2. J Clin Invest. 1986 Aug; 78(2):582-6.
    View in: PubMed
    Score: 0.060
  31. Multiple sclerosis: activated cells in cerebrospinal fluid in acute exacerbations. Ann Neurol. 1985 Dec; 18(6):722-5.
    View in: PubMed
    Score: 0.057
  32. Multiple sclerosis: relation of in vitro IgG secretion to T suppressor cell number and function. Neurology. 1984 Sep; 34(9):1155-60.
    View in: PubMed
    Score: 0.053
  33. Low T8 antigen density on lymphocytes in active multiple sclerosis. Ann Neurol. 1984 Aug; 16(2):242-9.
    View in: PubMed
    Score: 0.052
  34. Analysis of T regulator cell surface markers and functional properties in multiple sclerosis. J Neuroimmunol. 1984 Apr; 6(2):93-103.
    View in: PubMed
    Score: 0.051
  35. T regulator cell surface antigens in multiple sclerosis. Ann N Y Acad Sci. 1984; 436:247-53.
    View in: PubMed
    Score: 0.050
  36. Immunoregulation in multiple sclerosis. Ann N Y Acad Sci. 1984; 436:133-9.
    View in: PubMed
    Score: 0.050
  37. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Nov 25; 61(10):1332-8.
    View in: PubMed
    Score: 0.050
  38. Issues and practices in multiple sclerosis. Neurorehabil Neural Repair. 2002 Dec; 16(4):307-20.
    View in: PubMed
    Score: 0.047
  39. Modulation of T-lymphocyte differentiation antigens: potential relevance for multiple sclerosis. Proc Natl Acad Sci U S A. 1982 May; 79(10):3330-4.
    View in: PubMed
    Score: 0.045
  40. Defective mitogenic responses in myasthenia gravis and multiple sclerosis. Ann Neurol. 1982 May; 11(5):456-62.
    View in: PubMed
    Score: 0.045
  41. Multiple sclerosis: current concepts and management. Hosp Pract (Off Ed). 1982 Feb; 17(2):81-9.
    View in: PubMed
    Score: 0.044
  42. Influence of azathioprine (imuran) on in vitro immune function in multiple sclerosis. Ann Neurol. 1982 Feb; 11(2):177-81.
    View in: PubMed
    Score: 0.044
  43. Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neurosci. 2002 Jan 01; 22(1):123-32.
    View in: PubMed
    Score: 0.044
  44. Comparison of agar gel electrophoresis and isoelectric focusing in multiple sclerosis and subacute sclerosing panencephalitis. Ann Neurol. 1981 Jan; 9(1):34-41.
    View in: PubMed
    Score: 0.041
  45. Comparison between antibody-induced modulation of suppressor cells and suppressor cell changes in multiple sclerosis. Trans Am Neurol Assoc. 1981; 106:233-6.
    View in: PubMed
    Score: 0.041
  46. Detection of in vivo stimulated cerebrospinal-fluid lymphocytes by flow cytometry in patients with multiple sclerosis. N Engl J Med. 1980 Sep 25; 303(13):713-7.
    View in: PubMed
    Score: 0.040
  47. Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature. 1980 Sep 25; 287(5780):335-7.
    View in: PubMed
    Score: 0.040
  48. Immunoregulation in multiple sclerosis. Ann Neurol. 1980 Sep; 8(3):237-40.
    View in: PubMed
    Score: 0.040
  49. Mitogen responsiveness and suppressor cell function in multiple sclerosis. Influence of age and disease activity. Neurology. 1978 Oct; 28(10):999-1003.
    View in: PubMed
    Score: 0.035
  50. Lymphocyte function and the role of regulator cells in multiple sclerosis. Neurology. 1978 Sep; 28(9 Pt 2):106-10.
    View in: PubMed
    Score: 0.035
  51. Suppressor cell function in multiple sclerosis. Ann Immunol (Paris). 1978 Feb-Mar; 129(2-3):159-70.
    View in: PubMed
    Score: 0.033
  52. Contrasting defects of T-lymphocyte mitogenic response in multiple sclerosis and myasthenia gravis. Trans Am Neurol Assoc. 1978; 103:191-3.
    View in: PubMed
    Score: 0.033
  53. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996 Jul; 47(1):129-39.
    View in: PubMed
    Score: 0.030
  54. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996 Jan; 46(1):12-8.
    View in: PubMed
    Score: 0.029
  55. Proceedings: Immunogenetic aspects of demyelinating disease. Neurology. 1975 May; 25(5):489.
    View in: PubMed
    Score: 0.028
  56. Histocompatibility types and measles antibodies in multiple sclerosis and optic neuritis. J Neurol Sci. 1974 Aug; 22(4):419-28.
    View in: PubMed
    Score: 0.026
  57. The function of the CD2 protein is abnormal in multiple sclerosis. J Autoimmun. 1991 Jun; 4(3):479-91.
    View in: PubMed
    Score: 0.021
  58. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991 Apr; 32(1):67-74.
    View in: PubMed
    Score: 0.021
  59. Etiologic correlations between idiopathic polyneuritis and multiple sclerosis: therapeutic implications. Mod Treat. 1970 Sep; 7(5):903-17.
    View in: PubMed
    Score: 0.020
  60. Comparison of T8+ cell-mediated suppressor and cytotoxic functions in multiple sclerosis. J Neuroimmunol. 1986 Sep; 12(3):215-24.
    View in: PubMed
    Score: 0.015
  61. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol. 1979 Apr; 5(4):338-42.
    View in: PubMed
    Score: 0.009
  62. Experimental allergic encephalomyelitis. Passive transfer by the intraocular injection of sensitized cells. Arch Neurol. 1976 Mar; 33(3):183-5.
    View in: PubMed
    Score: 0.007
  63. A study of B and T cells in multiple sclerosis. Neurology. 1975 May; 25(5):444-7.
    View in: PubMed
    Score: 0.007
  64. Parainfluenza, histocompatibility, and multiple sclerosis. Association of parainfluenza antibodies and histocompatibility types in MS and optic neuritis. Arch Neurol. 1974 Apr; 30(4):327-9.
    View in: PubMed
    Score: 0.006
  65. Effects of estrogen, progestin and combined estrogen-progestin oral contraceptive preparations on experimental allergic encephalomyelitis. Trans Am Neurol Assoc. 1969; 94:54-8.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.